Eribulin Injection

Generic name: Pronounced as (er'' i bue' lin)
Brand names
  • Halaven®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 02/01/2011

Eribulin injection is used to treat breast cancer that has spread to other parts of the body and that has already been treated with certain other chemotherapy medications. Eribulin is in a class of anticancer medications called microtubule dynamics inhibitors. It works by stopping the growth and spread of cancer cells.

Eribulin injection comes as a solution (liquid) to be given intravenously (into a vein) over 2 to 5 minutes by a doctor or nurse in a medical office, infusion center, or hospital. It is usually given on days 1 and 8 of a 21-day cycle.

Your doctor may need to delay your treatment or decrease your dose if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before receiving eribulin injection,

  • tell your doctor and pharmacist if you are allergic to eribulin, any other medications, or any of the ingredients in eribulin injection. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone), clarithromycin (Biaxin); disopyramide (Norpace), dofetilide (Tikosyn), dronedarone (Multaq); erythromycin (E.E.S., E-Mycin, Erythrocin), ibutilide (Corvert); certain medications for mental illness such as chlorpromazine, haloperidol (Haldol), and thioridazine; methadone (Dolophine), moxifloxacin (Avelox), pimozide (Orap), procainamide, quinidine, and sotalol (Betapace, Betapace AF),. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have or have ever had long QT syndrome (condition that increases the risk of developing an irregular heartbeat that may cause loss of consciousness or sudden death); a slow heartbeat; low levels of potassium or magnesium in your blood; or heart, liver, or kidney disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while receiving eribulin injection, call your doctor. You should use birth control to prevent pregnancy during your treatment with eribulin injection.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving eribulin injection.

Unless your doctor tells you otherwise, continue your normal diet.

  • Eribulin injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • constipation

    • loss of appetite

    • weight loss

    • headache

    • weakness

    • tiredness

    • bone, back, or joint pain

    • hair loss

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:

    • sore throat, cough, fever (temperature greater than 100.5), chills, burning or pain when urinating, or other signs of infection

    • numbness, burning, or tingling in the arms, legs, hands, or feet

    • pale skin

    • shortness of breath

    • irregular heartbeat

  • Eribulin injection may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • sore throat, cough, fever, chills, burning or pain when urinating, or other signs of infection

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to eribulin injection.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Moxifloxacin.
Leflunomide Leflunomide The risk or severity of adverse effects can be increased when Eribulin is combined with Leflunomide.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dolasetron.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Anagrelide.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Eribulin.
Clopidogrel Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Eribulin.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erythromycin.
Mycophenolate Mycophenolate The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Eribulin.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Eribulin is combined with Acebutolol.
Prednisone Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Eribulin.
Tacrolimus Tacrolimus Tacrolimus may increase the immunosuppressive activities of Eribulin.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Eribulin.
Triamcinolone Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Eribulin.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Eribulin.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Eribulin.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Eribulin.
Interferon Beta-1b Injection Interferon Beta-1b Injection The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Eribulin.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Eribulin.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Levofloxacin.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Eribulin.
Metoclopramide Injection Metoclopramide Injection The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Eribulin.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Eribulin.
Zidovudine Injection Zidovudine Injection The risk or severity of adverse effects can be increased when Zidovudine is combined with Eribulin.
Cyclosporine Cyclosporine Eribulin may increase the immunosuppressive activities of Cyclosporine.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ondansetron.
Enoxaparin Injection Enoxaparin Injection The risk or severity of bleeding can be increased when Enoxaparin is combined with Eribulin.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Eribulin is combined with Granisetron.
Olanzapine Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Eribulin.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dofetilide.
Hydroxychloroquine Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Eribulin.
Temozolomide Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Eribulin.
Anakinra Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Eribulin.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Desloratadine.
Linezolid Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Eribulin.
Pentosan Polysulfate Pentosan Polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Eribulin.
Trimipramine Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Eribulin.
Etanercept Injection Etanercept Injection The risk or severity of adverse effects can be increased when Etanercept is combined with Eribulin.
Sirolimus Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Eribulin.
Epirubicin Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Eribulin.
Escitalopram Escitalopram The risk or severity of QTc prolongation can be increased when Eribulin is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Eribulin.
Adalimumab Injection Adalimumab Injection The risk or severity of adverse effects can be increased when Adalimumab is combined with Eribulin.
Aripiprazole Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Eribulin.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Eribulin.
Glatiramer Injection Glatiramer Injection The risk or severity of adverse effects can be increased when Glatiramer is combined with Eribulin.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Eribulin.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Eribulin.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Eribulin.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Eribulin.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gemifloxacin.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Eribulin.
Darbepoetin Alfa Injection Darbepoetin Alfa Injection The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Eribulin.
Infliximab Injection Infliximab Injection The risk or severity of adverse effects can be increased when Infliximab is combined with Eribulin.
Protriptyline Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Eribulin.
Natalizumab Injection Natalizumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Natalizumab.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erlotinib.
Palifermin Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Eribulin.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Eribulin.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Eribulin.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Eribulin.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Eribulin.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eribulin.
Pregabalin Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Eribulin.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Eribulin.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ranolazine.
Abatacept Injection Abatacept Injection The risk or severity of adverse effects can be increased when Abatacept is combined with Eribulin.
Imatinib Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Eribulin.
Bevacizumab Injection Bevacizumab Injection The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eribulin.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Eribulin.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Eribulin is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Eribulin.
Clofarabine Injection Clofarabine Injection The risk or severity of adverse effects can be increased when Clofarabine is combined with Eribulin.
Hepatitis B Vaccine Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Eribulin.
Influenza Vaccine, Inactivated or Recombinant Influenza Vaccine, Inactivated or Recombinant The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Eribulin.
Influenza Vaccine, Live Intranasal Influenza Vaccine, Live Intranasal The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Eribulin.
Live Shingles (Zoster) Vaccine (ZVL) Live Shingles (Zoster) Vaccine (ZVL) The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/attenuated) is combined with Eribulin.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eribulin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Eribulin.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Primaquine.
Rituximab Injection Rituximab Injection The risk or severity of adverse effects can be increased when Rituximab is combined with Eribulin.
Pemetrexed Injection Pemetrexed Injection The risk or severity of adverse effects can be increased when Pemetrexed is combined with Eribulin.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dimenhydrinate.
Vorinostat Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Eribulin.
Sorafenib Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Eribulin.
Sunitinib Sunitinib The risk or severity of adverse effects can be increased when Sunitinib is combined with Eribulin.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Eribulin.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Eribulin.
Dasatinib Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Eribulin.
Azacitidine Injection Azacitidine Injection The risk or severity of adverse effects can be increased when Azacitidine is combined with Eribulin.
Temsirolimus Temsirolimus The risk or severity of adverse effects can be increased when Temsirolimus is combined with Eribulin.
Nelarabine Injection Nelarabine Injection The risk or severity of adverse effects can be increased when Nelarabine is combined with Eribulin.
Lenalidomide Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Eribulin.
Nilotinib Nilotinib The risk or severity of adverse effects can be increased when Nilotinib is combined with Eribulin.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Eribulin is combined with Toremifene.
Bexarotene Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Eribulin.
Budesonide Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Eribulin.
Chloramphenicol Injection Chloramphenicol Injection The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Eribulin.
Decitabine Injection Decitabine Injection The risk or severity of adverse effects can be increased when Decitabine is combined with Eribulin.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eribulin.
Mitoxantrone Injection Mitoxantrone Injection The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Eribulin.
Tretinoin Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Eribulin.
Bendamustine Injection Bendamustine Injection The risk or severity of adverse effects can be increased when Bendamustine is combined with Eribulin.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Flecainide.
Certolizumab Injection Certolizumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The risk or severity of adverse effects can be increased when Ixabepilone is combined with Eribulin.
Irinotecan Injection Irinotecan Injection The risk or severity of adverse effects can be increased when Irinotecan is combined with Eribulin.
Estramustine Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Eribulin.
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eribulin.
Dexrazoxane Injection Dexrazoxane Injection The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eribulin.
Ibritumomab Injection Ibritumomab Injection The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Eribulin.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Eribulin is combined with Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Eribulin is combined with Iloperidone.
Prasugrel Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Eribulin.
Everolimus Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Eribulin.
Dronedarone Dronedarone The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dronedarone.
Pralatrexate Injection Pralatrexate Injection The risk or severity of adverse effects can be increased when Pralatrexate is combined with Eribulin.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Romidepsin.
Topotecan Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Eribulin.
Golimumab Injection Golimumab Injection The risk or severity of adverse effects can be increased when Golimumab is combined with Eribulin.
Pazopanib Pazopanib The risk or severity of adverse effects can be increased when Pazopanib is combined with Eribulin.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Asenapine.
Denosumab Injection Denosumab Injection The risk or severity of adverse effects can be increased when Denosumab is combined with Eribulin.
Dabigatran Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Eribulin.
Tocilizumab Injection Tocilizumab Injection The risk or severity of adverse effects can be increased when Tocilizumab is combined with Eribulin.
Fingolimod Fingolimod Eribulin may increase the immunosuppressive activities of Fingolimod.
Cabazitaxel Injection Cabazitaxel Injection The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Eribulin.
Denileukin Diftitox Injection Denileukin Diftitox Injection The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eribulin.
Sipuleucel-T Injection Sipuleucel-T Injection The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Eribulin.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Eribulin.
Belimumab Injection Belimumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Belimumab.
Busulfan Injection Busulfan Injection The risk or severity of adverse effects can be increased when Busulfan is combined with Eribulin.
Roflumilast Roflumilast Roflumilast may increase the immunosuppressive activities of Eribulin.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Eribulin.
Cyclophosphamide Injection Cyclophosphamide Injection The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Eribulin.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eribulin.
Rivaroxaban Rivaroxaban The risk or severity of bleeding can be increased when Rivaroxaban is combined with Eribulin.
Ticagrelor Ticagrelor The risk or severity of bleeding can be increased when Ticagrelor is combined with Eribulin.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eribulin.
Ruxolitinib Ruxolitinib The risk or severity of adverse effects can be increased when Eribulin is combined with Ruxolitinib.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Vandetanib.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Vemurafenib.
Belatacept Injection Belatacept Injection The risk or severity of adverse effects can be increased when Belatacept is combined with Eribulin.
Basiliximab Injection Basiliximab Injection The risk or severity of adverse effects can be increased when Basiliximab is combined with Eribulin.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Crizotinib.
Melphalan Injection Melphalan Injection The risk or severity of adverse effects can be increased when Melphalan is combined with Eribulin.
Eculizumab Injection Eculizumab Injection The risk or severity of adverse effects can be increased when Eculizumab is combined with Eribulin.
Fondaparinux Injection Fondaparinux Injection The risk or severity of bleeding can be increased when Fondaparinux is combined with Eribulin.
Carfilzomib Injection Carfilzomib Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Carfilzomib.
Iloprost Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Eribulin.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mirabegron.
Bosutinib Bosutinib The risk or severity of adverse effects can be increased when Bosutinib is combined with Eribulin.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of adverse effects can be increased when Corticotropin is combined with Eribulin.
Teriflunomide Teriflunomide The risk or severity of adverse effects can be increased when Eribulin is combined with Teriflunomide.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Eribulin is combined with Bedaquiline.
Icosapent Ethyl Icosapent Ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Eribulin.
Tofacitinib Tofacitinib Eribulin may increase the immunosuppressive activities of Tofacitinib.
Dimethyl Fumarate Dimethyl Fumarate The risk or severity of adverse effects can be increased when Eribulin is combined with Dimethyl fumarate.
Ponatinib Ponatinib The risk or severity of adverse effects can be increased when Eribulin is combined with Ponatinib.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Eribulin is combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eribulin.
Apixaban Apixaban The risk or severity of bleeding can be increased when Apixaban is combined with Eribulin.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dabrafenib.
Ibrutinib Ibrutinib The risk or severity of adverse effects can be increased when Eribulin is combined with Ibrutinib.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Obinutuzumab.
Apremilast Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Eribulin.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ceritinib.
Siltuximab Injection Siltuximab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Siltuximab.
Vedolizumab Injection Vedolizumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Vedolizumab.
Belinostat Injection Belinostat Injection The risk or severity of adverse effects can be increased when Belinostat is combined with Eribulin.
Idelalisib Idelalisib The risk or severity of adverse effects can be increased when Eribulin is combined with Idelalisib.
Vorapaxar Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Eribulin.
Edoxaban Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Eribulin.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Peginterferon beta-1a.
Olaparib Olaparib The risk or severity of adverse effects can be increased when Eribulin is combined with Olaparib.
Blinatumomab Injection Blinatumomab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Blinatumomab.
Pirfenidone Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Eribulin.
Secukinumab Injection Secukinumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of QTc prolongation can be increased when Risperidone is combined with Eribulin.
Palbociclib Palbociclib The risk or severity of adverse effects can be increased when Eribulin is combined with Palbociclib.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Eribulin.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Dinutuximab.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ivabradine.
Prednisolone Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Eribulin.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ziprasidone.
Mepolizumab Injection Mepolizumab Injection The risk or severity of adverse effects can be increased when Mepolizumab is combined with Eribulin.
Trabectedin Injection Trabectedin Injection The risk or severity of adverse effects can be increased when Trabectedin is combined with Eribulin.
Dexamethasone Injection Dexamethasone Injection The risk or severity of adverse effects can be increased when Dexamethasone is combined with Eribulin.
Defibrotide Injection Defibrotide Injection The risk or severity of bleeding can be increased when Defibrotide is combined with Eribulin.
Ixekizumab Injection Ixekizumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Ixekizumab.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Eribulin.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ribociclib.
Brodalumab Injection Brodalumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Brodalumab.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of QTc prolongation can be increased when Doxepin is combined with Eribulin.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Deutetrabenazine.
Deflazacort Deflazacort The risk or severity of adverse effects can be increased when Eribulin is combined with Deflazacort.
Ocrelizumab Injection Ocrelizumab Injection Ocrelizumab may increase the immunosuppressive activities of Eribulin.
Sarilumab Injection Sarilumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Sarilumab.
Guselkumab Injection Guselkumab Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Guselkumab.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Delafloxacin.
Betrixaban Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Eribulin.
Gemtuzumab Ozogamicin Injection Gemtuzumab Ozogamicin Injection The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Tetrabenazine.
Penicillamine Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Eribulin.
Baricitinib Baricitinib The risk or severity of adverse effects can be increased when Eribulin is combined with Baricitinib.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Eribulin is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ivosidenib.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Glasdegib.
Methoxy Polyethylene Glycol-Epoetin Beta Injection Methoxy Polyethylene Glycol-Epoetin Beta Injection The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Eribulin.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin.
Ravulizumab-cwvz Injection Ravulizumab-cwvz Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Ravulizumab.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Emapalumab.
Siponimod Siponimod The risk or severity of adverse effects can be increased when Eribulin is combined with Siponimod.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of bleeding can be increased when Caplacizumab is combined with Eribulin.
Risankizumab-rzaa Injection Risankizumab-rzaa Injection The risk or severity of adverse effects can be increased when Eribulin is combined with Risankizumab.
Cladribine Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Eribulin.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Eribulin is combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Eribulin is combined with Entrectinib.
Pitolisant Pitolisant Eribulin may increase the QTc-prolonging activities of Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Eribulin.
Ozanimod Ozanimod The risk or severity of adverse effects can be increased when Eribulin is combined with Ozanimod.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fostemsavir.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eribulin.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Eribulin is combined with Relugolix.
Indomethacin Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Eribulin.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Eribulin.
Hydroxyurea Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Eribulin.
Floxuridine Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Eribulin.
Methotrexate Injection Methotrexate Injection The risk or severity of adverse effects can be increased when Methotrexate is combined with Eribulin.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Eribulin.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorpromazine.
Carmustine Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Eribulin.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Eribulin.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Eribulin.
Thioguanine Thioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Eribulin.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Thioridazine.
Bleomycin Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Eribulin.
Methadone Methadone The risk or severity of QTc prolongation can be increased when Eribulin is combined with Methadone.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Eribulin.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Eribulin.
Orphenadrine Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Eribulin.
Azathioprine Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Eribulin.
Amoxapine Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Eribulin.
Sulfasalazine Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Eribulin.
Lomustine Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Eribulin.
Doxorubicin Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Eribulin.
Cytarabine Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Eribulin.
Mechlorethamine Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Eribulin.
Dactinomycin Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Eribulin.
Carbamazepine Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Eribulin.
Warfarin Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Eribulin.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Loperamide.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Eribulin.
Daunorubicin Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Eribulin.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chloroquine.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Eribulin.
Sulfinpyrazone Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Eribulin.
Chlorothiazide Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Eribulin.
Desipramine Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Eribulin.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Eribulin is combined with Amitriptyline.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Imipramine.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Procainamide.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Eribulin is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Eribulin.
Mitomycin Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Eribulin.
Methimazole Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Eribulin.
Propylthiouracil Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Eribulin.
Doxylamine Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Eribulin.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Eribulin.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Eribulin.
Methyclothiazide Methyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Eribulin.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Eribulin.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Eribulin.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Eribulin is combined with Propranolol.
Nortriptyline Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Eribulin.
Mercaptopurine Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Eribulin.
Allopurinol Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Eribulin.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eribulin.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eribulin.
Colchicine Colchicine The risk or severity of adverse effects can be increased when Colchicine is combined with Eribulin.
Dacarbazine Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Eribulin.
Bacillus Calmette-Guerin (BCG) Vaccine Bacillus Calmette-Guerin (BCG) Vaccine The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Eribulin.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Eribulin.
Thiotepa Injection Thiotepa Injection The risk or severity of adverse effects can be increased when Thiotepa is combined with Eribulin.
Vincristine Injection Vincristine Injection The risk or severity of adverse effects can be increased when Vincristine is combined with Eribulin.
Dipyridamole Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Eribulin.
Vinblastine Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Eribulin.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Eribulin.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Eribulin.
Aspirin Aspirin The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Eribulin.
Chlorambucil Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Eribulin.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Eribulin.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Eribulin is combined with Diltiazem.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nifedipine.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Eribulin.
Cisplatin Injection Cisplatin Injection The risk or severity of adverse effects can be increased when Cisplatin is combined with Eribulin.
Streptozocin Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Eribulin.
Etoposide Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Eribulin.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Eribulin.
Pentoxifylline Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Eribulin.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pentamidine.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Leuprolide.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pimozide.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Eribulin is combined with Amiodarone.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ciprofloxacin.
Fluoxetine Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Eribulin.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nimodipine.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Eribulin.
Clozapine Clozapine The risk or severity of neutropenia can be increased when Eribulin is combined with Clozapine.
Idarubicin Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Eribulin.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ofloxacin.
Fludarabine Injection Fludarabine Injection The risk or severity of adverse effects can be increased when Fludarabine is combined with Eribulin.
Pentostatin Injection Pentostatin Injection The risk or severity of adverse effects can be increased when Pentostatin is combined with Eribulin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Clarithromycin.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Eribulin.
Epoetin Alfa, Injection Epoetin Alfa, Injection The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Eribulin.
Teniposide Injection Teniposide Injection The risk or severity of adverse effects can be increased when Teniposide is combined with Eribulin.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Eribulin.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sotalol.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Eribulin.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cisapride.
Venlafaxine Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Eribulin.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Eribulin.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Eribulin.
Vinorelbine Injection Vinorelbine Injection The risk or severity of adverse effects can be increased when Vinorelbine is combined with Eribulin.
Carboplatin Injection Carboplatin Injection The risk or severity of adverse effects can be increased when Carboplatin is combined with Eribulin.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Eribulin.
Ifosfamide Injection Ifosfamide Injection The risk or severity of adverse effects can be increased when Ifosfamide is combined with Eribulin.
Pegaspargase Injection Pegaspargase Injection The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eribulin.
Nicardipine Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Eribulin.
Ticlopidine Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Eribulin.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Eribulin is combined with Saquinavir.
Dalteparin Injection Dalteparin Injection The risk or severity of bleeding can be increased when Dalteparin is combined with Eribulin.
Gemcitabine Injection Gemcitabine Injection The risk or severity of adverse effects can be increased when Gemcitabine is combined with Eribulin.
Ritonavir Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Eribulin.
Docetaxel Injection Docetaxel Injection The risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Clomipramine.
Mirtazapine Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Eribulin.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Eribulin.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Azithromycin.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Eribulin is combined with Propafenone.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Eribulin.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Eribulin is combined with Citalopram.
Capecitabine Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Eribulin.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Eribulin is combined with Efavirenz.
Trastuzumab Injection Trastuzumab Injection Trastuzumab may increase the neutropenic activities of Eribulin.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Eribulin.
Thalidomide Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Eribulin.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Eribulin.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists